Amgen study data bolster prospects of KRAS-blocking cancer drug

A first-of-its-kind drug developed by Amgen shrank tumors in a little over a third of lung cancer patients enrolled into a mid-sized study, affirming promising results from an earlier trial that had excited oncologists and made the medicine one of the most closely watched in biotech.